Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 523

1.

High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.

Elmowafy AY, El Maghrabi HM, Mashaly ME, Eldahshan KF, Rostaing L, Bakr MA.

Int Urol Nephrol. 2019 Oct 14. doi: 10.1007/s11255-019-02316-w. [Epub ahead of print]

PMID:
31612423
2.

[How to implement a complete apheresis program within a hemodialysis unit].

Maurizi-Balzan J, Jouve T, Naciri-Bennani H, Noble J, Tanoukhi K, Motte L, Malvezzi P, Rostaing L.

Nephrol Ther. 2019 Oct 1. pii: S1769-7255(19)30170-1. doi: 10.1016/j.nephro.2019.01.005. [Epub ahead of print] French.

PMID:
31585841
3.

Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.

Maghrabi HME, Elmowafy AY, Refaie AF, Elbasiony MA, Shiha GE, Rostaing L, Bakr MA.

Int Urol Nephrol. 2019 Sep 17. doi: 10.1007/s11255-019-02272-5. [Epub ahead of print]

PMID:
31531807
4.

Immunosuppression and Graft Rejection in Living-Related HLA-Identical Renal Transplantation: The RADOVFULL Study.

Ossman R, Jamme M, Moulin B, Legendre C, Morelon E, Frimat L, Hourmant M, Durrbach A, Malvezzi P, Rostaing L, Taupin JL, Mesnard L, Rondeau E; RADOVFULL Study Group.

Transplantation. 2019 Aug 27. doi: 10.1097/TP.0000000000002937. [Epub ahead of print]

PMID:
31465001
5.

The TOMATO study (TacrOlimus MetabolizAtion in kidney TransplantatiOn): impact of the concentration-dose ratio on death-censored graft survival.

Jouve T, Fonrose X, Noble J, Janbon B, Fiard G, Malvezzi P, Stanke-Labesque F, Rostaing L.

Transplantation. 2019 Aug 12. doi: 10.1097/TP.0000000000002920. [Epub ahead of print]

PMID:
31415035
6.

Impact of Adopting Routine Luminex-Based Pretransplant Assessment of HLA Antibodies on Clinical Practice and Outcomes in Kidney Transplantation.

NasrAllah MM, Elalfy MM, Fakhry SA, Rostaing L, Amer I, Elmeseery YA, Mohammed IS, El-Gamal AM, Malvezzi P.

Transplant Proc. 2019 Sep;51(7):2241-2244. doi: 10.1016/j.transproceed.2019.01.147. Epub 2019 Aug 7.

PMID:
31400974
7.

Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.

Elmowafy AY, El Maghrabi HM, Eldahshan KF, Refaie AF, Elbasiony MA, Matter YE, Saleh HH, Shiha GE, Rostaing L, Bakr MA.

Int Urol Nephrol. 2019 Sep;51(9):1639-1647. doi: 10.1007/s11255-019-02246-7. Epub 2019 Jul 30.

PMID:
31363959
8.

Hemodialysis coupled with rheopheresis in calciphylaxis: A winning combination.

Naciri Bennani H, Jouve T, Boudjemaa S, Gil H, Rostaing L.

J Clin Apher. 2019 Oct;34(5):631-633. doi: 10.1002/jca.21736. Epub 2019 Jul 19. No abstract available.

PMID:
31322751
9.

The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study.

Trunečka P, Klempnauer J, Bechstein WO, Pirenne J, Bennet W, Zhao A, Isoniemi H, Rostaing L, Settmacher U, Mönch C, Brown M, Undre N, Kazeem G, Tisone G.

Ann Transplant. 2019 Jun 4;24:319-327. doi: 10.12659/AOT.913103.

10.

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient.

Manière L, Domenger C, Camara B, Giovannini D, Malvezzi P, Rostaing L.

Case Rep Transplant. 2019 Apr 11;2019:9465040. doi: 10.1155/2019/9465040. eCollection 2019.

11.

Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.

Malvezzi P, Fischman C, Rigault G, Jacob MC, Raskovalova T, Jouve T, Janbon B, Rostaing L, Cravedi P.

Transpl Immunol. 2019 Oct;56:101207. doi: 10.1016/j.trim.2019.04.002. Epub 2019 May 6.

PMID:
31071442
12.

Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.

Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, Grinyó J, Mamode N, Rigotti P, Couzi L, Büchler M, Sandrini S, Dain B, Garfield M, Ogawa M, Richard T, Marks WH; C10-002 Study Group.

Am J Transplant. 2019 Oct;19(10):2865-2875. doi: 10.1111/ajt.15397. Epub 2019 May 24.

PMID:
31012541
13.

An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization.

Jouve T, Noble J, Rostaing L, Malvezzi P.

Expert Opin Drug Saf. 2019 Apr;18(4):285-294. doi: 10.1080/14740338.2019.1599858. Epub 2019 Apr 1. Review.

PMID:
30909754
14.

Effects of immunoadsorption combined with membrane filtration on complement markers - results of a randomized, controlled, crossover study.

Defendi F, Malvezzi P, Eskandary F, Cesbron JY, Rostaing L, Böhmig GA, Dumestre-Pérard C.

Transpl Int. 2019 Aug;32(8):876-883. doi: 10.1111/tri.13431. Epub 2019 Apr 5.

PMID:
30901502
15.

[Living with end-stage renal failure].

Renaloo L, Rostaing L.

Rev Prat. 2018 Dec;68(10):1105-1106. French. No abstract available.

PMID:
30869219
16.

Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care.

Fournier MC, Foucher Y, Blanche P, Legendre C, Girerd S, Ladrière M, Morelon E, Buron F, Rostaing L, Kamar N, Mourad G, Garrigue V, Couvrat-Desvergnes G, Giral M, Dantan E; DIVAT Consortium.

Nephrol Dial Transplant. 2019 Mar 11. pii: gfz027. doi: 10.1093/ndt/gfz027. [Epub ahead of print]

PMID:
30859193
17.

Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors.

Gaillard F, Courbebaisse M, Kamar N, Rostaing L, Jacquemont L, Hourmant M, Del Bello A, Couzi L, Merville P, Malvezzi P, Janbon B, Moulin B, Maillard N, Dubourg L, Lemoine S, Garrouste C, Pottel H, Legendre C, Delanaye P, Mariat C.

Kidney Int. 2019 Apr;95(4):896-904. doi: 10.1016/j.kint.2018.11.029. Epub 2019 Feb 26.

PMID:
30819555
18.

[Lyme nephritis in humans: Physio-pathological bases and spectrum of kidney lesions].

Gueye S, Seck SM, Kane Y, Tosi PO, Dahri S, Kounde C, Algouzmari I, Gouin A, Ged É, Allal A, Rostaing L.

Nephrol Ther. 2019 Jun;15(3):127-135. doi: 10.1016/j.nephro.2018.09.004. Epub 2019 Jan 31. French.

PMID:
30713068
19.

Belatacept in kidney transplantation and its limitations.

Noble J, Jouve T, Janbon B, Rostaing L, Malvezzi P.

Expert Rev Clin Immunol. 2019 Apr;15(4):359-367. doi: 10.1080/1744666X.2019.1574570. Epub 2019 Feb 7.

PMID:
30676815
20.

Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.

Kamar N, Cassuto E, Piotti G, Govoni M, Ciurlia G, Geraci S, Poli G, Nicolini G, Mariat C, Essig M, Malvezzi P, Le Meur Y, Garrigue V, Del Bello A, Rostaing L.

Adv Ther. 2019 Feb;36(2):462-477. doi: 10.1007/s12325-018-0855-1. Epub 2018 Dec 14.

PMID:
30552587
21.

Systematic Screening Using Luminex for De Novo C3d Fixing of Class II Donor-Specific Antibodies Is Correlated With Luminex Mean Fluorescence Intensity in Renal Transplant Patients.

Villemaire M, Jouve T, Bourdin A, Janbon B, Pinel N, Tetaz R, Terrier N, Rostaing L, Masson D, Malvezzi P.

Exp Clin Transplant. 2019 Aug;17(4):483-489. doi: 10.6002/ect.2018.0063. Epub 2018 Oct 19.

22.

Renal complications of liver diseases.

Noble J, Jouve T, Malvezzi P, Rostaing L.

Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1135-1142. doi: 10.1080/17474124.2018.1530984. Epub 2018 Oct 11. Review.

PMID:
30269605
23.

Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease.

Heitz M, Carron PL, Clavarino G, Jouve T, Pinel N, Guebre-Egziabher F, Rostaing L.

BMC Nephrol. 2018 Sep 20;19(1):241. doi: 10.1186/s12882-018-1038-7.

24.

The age-calibrated measured glomerular filtration rate improves living kidney donation selection process.

Gaillard F, Courbebaisse M, Kamar N, Rostaing L, Del Bello A, Girerd S, Kessler M, Flamant M, Vidal-Petiot E, Peraldi MN, Couzi L, Merville P, Malvezzi P, Janbon B, Moulin B, Caillard S, Gatault P, Büchler M, Maillard N, Dubourg L, Roquet O, Garrouste C, Legendre C, Delanaye P, Mariat C.

Kidney Int. 2018 Sep;94(3):616-624. doi: 10.1016/j.kint.2018.05.016.

25.

Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?

Malvezzi P, Jouve T, Rostaing L.

EBioMedicine. 2018 Aug;34:2-3. doi: 10.1016/j.ebiom.2018.07.032. Epub 2018 Aug 7. No abstract available. Erratum in: EBioMedicine. 2018 Aug 23;:.

26.

Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study.

Couvrat-Desvergnes G, Foucher Y, Le Borgne F, Dion A, Mourad G, Garrigue V, Legendre C, Rostaing L, Kamar N, Kessler M, Ladrière M, Morelon E, Buron F, Giral M, Dantan E.

Nephrol Dial Transplant. 2019 Apr 1;34(4):703-711. doi: 10.1093/ndt/gfy221.

PMID:
30060106
27.

Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.

Dantal J, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, Del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra A, Hofbauer GFL, Kamar N, Pouteil-Noble C, Kanitakis J, Roux A, Decullier E, Euvrard S; TUMORAPA Study Group.

J Clin Oncol. 2018 Sep 1;36(25):2612-2620. doi: 10.1200/JCO.2017.76.6691. Epub 2018 Jul 17.

PMID:
30016177
28.

Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models.

Jouve T, Marlu R, Malvezzi P, Seyve L, Maurizi J, Carron PL, Polack B, Rostaing L.

Blood Purif. 2018;46(3):239-245. doi: 10.1159/000488928. Epub 2018 Jul 4.

PMID:
29972828
29.

Corrigendum to "Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation" [Thromb. Res. 166 (2018) 113-121].

Marlu R, Malvezzi P, Seyve L, Jouve T, Maurizi J, Defendi F, Carron PL, Christophe M, Le Gouellec A, Polack B, Rostaing L.

Thromb Res. 2018 Nov;171:200. doi: 10.1016/j.thromres.2018.05.033. Epub 2018 Jun 8. No abstract available.

PMID:
29887501
30.

Novel Approaches to Block Complement.

Böhmig GA, Wahrmann M, Eskandary F, Rostaing L.

Transplantation. 2018 Nov;102(11):1837-1843. doi: 10.1097/TP.0000000000002267. Review.

PMID:
29870459
31.

Desensitization in the Setting of HLA-Incompatible Kidney Transplant.

Malvezzi P, Jouve T, Noble J, Rostaing L.

Exp Clin Transplant. 2018 Aug;16(4):367-375. doi: 10.6002/ect.2017.0355. Epub 2018 Jun 1. Review.

32.

Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review.

Sautenet B, Tong A, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Evangelidis N, Craig JC.

Transplantation. 2018 Dec;102(12):2065-2071. doi: 10.1097/TP.0000000000002278.

PMID:
29781954
33.

Tailoring tacrolimus therapy in kidney transplantation.

Jouve T, Noble J, Rostaing L, Malvezzi P.

Expert Rev Clin Pharmacol. 2018 Jun;11(6):581-588. doi: 10.1080/17512433.2018.1479638. Epub 2018 May 25. Review.

PMID:
29779413
34.

Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.

Noble J, Jouve T, Rostaing L, Malvezzi P.

Expert Rev Clin Immunol. 2018 Jun;14(6):461-467. doi: 10.1080/1744666X.2018.1476850. Epub 2018 May 21. Review.

PMID:
29757021
35.

Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation.

Marlu R, Malvezzi P, Seyve L, Jouve T, Maurizi J, Defendi F, Carron PL, Christophe M, Le Gouellec A, Polack B, Rostaing L.

Thromb Res. 2018 Jun;166:113-121. doi: 10.1016/j.thromres.2018.04.018. Epub 2018 Apr 20. Erratum in: Thromb Res. 2018 Jun 7;:.

PMID:
29747114
36.

Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation.

Mai HL, Treilhaud M, Ben-Arye SL, Yu H, Perreault H, Ang E, Trébern-Launay K, Laurent J, Malard-Castagnet S, Cesbron A, Nguyen TVH, Brouard S, Rostaing L, Houssel-Debry P, Legendre C, Girerd S, Kessler M, Morelon E, Sicard A, Garrigue V, Karam G, Chen X, Giral M, Padler-Karavani V, Soulillou JP.

Transplant Direct. 2018 Mar 20;4(4):e357. doi: 10.1097/TXD.0000000000000772. eCollection 2018 Apr.

37.

[Renal transplantation].

Rostaing L.

Nephrol Ther. 2017 Jun;13(6S):6S25-6S29. doi: 10.1016/S1769-7255(18)30037-3. Review. French.

PMID:
29463396
38.

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.

Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP.

Clin Transplant. 2018 Apr;32(4):e13225. doi: 10.1111/ctr.13225. Epub 2018 Mar 14.

PMID:
29461660
39.

Intravenous Immunoglobulins in the Prevention of Rejection of a Second or Third Kidney Graft.

Glotz D, Rostaing L, Merville P, Squifflet JP, Lebranchu Y.

Transplant Proc. 2018 Jan - Feb;50(1):70-71. doi: 10.1016/j.transproceed.2017.11.010.

PMID:
29407334
40.

Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors.

Querard AH, Le Borgne F, Dion A, Giral M, Mourad G, Garrigue V, Rostaing L, Kamar N, Loupy A, Legendre C, Morelon E, Buron F, Foucher Y, Dantan E.

Am J Transplant. 2018 May;18(5):1151-1157. doi: 10.1111/ajt.14651. Epub 2018 Feb 8.

41.

Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.

Marquet P, Albano L, Woillard JB, Rostaing L, Kamar N, Sakarovitch C, Gatault P, Buchler M, Charpentier B, Thervet E, Cassuto E.

Pharmacol Res. 2018 Mar;129:84-94. doi: 10.1016/j.phrs.2017.12.005. Epub 2017 Dec 8.

PMID:
29229354
42.

Transplantation: IdeS to desensitize organ allograft recipients.

Böhmig GA, Rostaing L.

Nat Rev Nephrol. 2017 Nov;13(11):666-668. doi: 10.1038/nrneph.2017.128. Epub 2017 Sep 11. No abstract available.

PMID:
28890539
43.

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals.

Sautenet B, Tong A, Manera KE, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Hanson CS, O'Donoghue D, Tam-Tham H, Halimi JM, Shen JI, Kanellis J, Scandling JD, Howard K, Howell M, Cross N, Evangelidis N, Masson P, Oberbauer R, Fung S, Jesudason S, Knight S, Mandayam S, McDonald SP, Chadban S, Rajan T, Craig JC.

Transplantation. 2017 Aug;101(8):1875-1886. doi: 10.1097/TP.0000000000001776.

44.

Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops.

Tong A, Gill J, Budde K, Marson L, Reese PP, Rosenbloom D, Rostaing L, Wong G, Josephson MA, Pruett TL, Warrens AN, Craig JC, Sautenet B, Evangelidis N, Ralph AF, Hanson CS, Shen JI, Howard K, Meyer K, Perrone RD, Weiner DE, Fung S, Ma MKM, Rose C, Ryan J, Chen LX, Howell M, Larkins N, Kim S, Thangaraju S, Ju A, Chapman JR; SONG-Tx Investigators.

Transplantation. 2017 Aug;101(8):1887-1896. doi: 10.1097/TP.0000000000001774.

45.

New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.

Jouve T, Rostaing L, Malvezzi P.

Expert Opin Drug Saf. 2017 Jul;16(7):845-855. doi: 10.1080/14740338.2017.1328051. Epub 2017 May 31. Review.

PMID:
28494654
46.

Renal transplantation in 2016: Novel approaches to improve recipient and allograft outcomes.

Malvezzi P, Rostaing L.

Nat Rev Nephrol. 2017 Jan 19;13(2):73-74. doi: 10.1038/nrneph.2016.190. Review. No abstract available.

PMID:
28100905
47.

Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.

Gatault P, Kamar N, Büchler M, Colosio C, Bertrand D, Durrbach A, Albano L, Rivalan J, Le Meur Y, Essig M, Bouvier N, Legendre C, Moulin B, Heng AE, Weestel PF, Sayegh J, Charpentier B, Rostaing L, Thervet E, Lebranchu Y.

Am J Transplant. 2017 May;17(5):1370-1379. doi: 10.1111/ajt.14109. Epub 2017 Jan 3.

48.

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Polinsky M, Meier-Kriesche HU, Munier S, Grinyó JM.

Am J Transplant. 2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830. Epub 2016 Jun 9.

49.

Costimulation Blockade in Kidney Transplantation: An Update.

Malvezzi P, Jouve T, Rostaing L.

Transplantation. 2016 Nov;100(11):2315-2323. Review.

50.

ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.

Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, Langer RM, Citterio F, Charpentier B, Brown M, Kazeem G, Lehner F; ADHERE study investigators.

Transpl Int. 2017 Jan;30(1):83-95. doi: 10.1111/tri.12878. Epub 2016 Nov 28.

Supplemental Content

Loading ...
Support Center